Fibovil Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 08-12-2024
- Paid Up Capital ₹ 0.10 M
as on 08-12-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.00 Cr
as on 08-12-2024
- Revenue 69.96%
(FY 2021)
- Profit 91.89%
(FY 2021)
- Ebitda 75.58%
(FY 2021)
- Net Worth 150.54%
(FY 2021)
- Total Assets 20.19%
(FY 2021)
About Fibovil Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 Cr.
Jagat Parkash, Reetu Rani, and Sahil serve as directors at the Company.
- CIN/LLPIN
U24239HR2019PTC079733
- Company No.
079733
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Apr 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Fibovil Pharmaceuticals Private Limited offer?
Fibovil Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Tablets, Nutraceuticals & Dietary Supplements, Fitness Supplements, Ayurvedic, Herbal Oils and Cosmetics, Aloe Vera Cosmetics, Anti Infective Drugs & Medicines, Malaria Medicine, Pharma & Bioanalytical Services, PCD Pharma Franchise.
Who are the key members and board of directors at Fibovil Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jagat Parkash  | Director | 20-Jun-2022 | Current |
| Reetu Rani | Director | 12-Apr-2019 | Current |
| Sahil | Director | 12-Apr-2019 | Current |
Financial Performance of Fibovil Pharmaceuticals.
Fibovil Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 69.96% increase. The company also saw a substantial improvement in profitability, with a 91.89% increase in profit. The company's net worth Soared by an impressive increase of 150.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fibovil Pharmaceuticals?
In 2023, Fibovil Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Covaxl Pharmaceuticals Private LimitedActive 1 year 6 monthsJagat Parkash and Sahil are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Apr 2024 | ₹3.00 Cr | Open |
Others Creation Date: 08 Feb 2023 | ₹2.00 Cr | Open |
How Many Employees Work at Fibovil Pharmaceuticals?
Fibovil Pharmaceuticals has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fibovil Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fibovil Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
